# Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

> **NCT00658320** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 122 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** Basiliximab
- **DRUG:** Cyclosporine A
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT00658320
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-08
- **Final completion:** 2012-05
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658320, "Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00658320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*